November/December 2016: Volume 17 Number 11/12
29 November 2016. Related: Editorial.
2016
UK Guide to PrEP (2nd Edition)
29 November 2016. Related: Supplements, HIV prevention and transmission.
International Congress of Drug Therapy in HIV infection (Glasgow 2016), 23-26 October 2016
29 November 2016. Related: Conference reports.
1000-fold mark-up for drug prices in high-income countries blocks access to HIV, HCV and cancer drugs
29 November 2016. Related: Conference reports, Treatment access.
Once-daily raltegravir formulation matches twice-daily results in age, gender, race and baseline viral load/CD4 subgroup analyses
29 November 2016. Related: Conference reports, Antiretrovirals.
Attachment inhibitor GSK-934/BMS-068: 96-week subgroup analysis in treatment-experienced patients
29 November 2016. Related: Conference reports, Antiretrovirals.
Once-weekly albuvirtide infusion: early results of T-20-like compound
29 November 2016. Related: Conference reports, Antiretrovirals.
Simplifying HIV treatment: dual therapy works but monotherapy with either boosted-PIs or dolutegravir does not
29 November 2016. Related: Conference reports, Treatment strategies.
Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients
29 November 2016. Related: Conference reports, PK and drug interactions, TB coinfection.
Further reports of CNS-related side effects with dolutegravir
29 November 2016. Related: Conference reports, Side effects.
Generic PrEP bought online for UK use is validated by drug testing service
29 November 2016. Related: Conference reports, HIV prevention and transmission.
Immunology and HIV persistence – implications for a cure
29 November 2016. Related: Conference reports, Cure-related research.
Selected webcasts from Glasgow 2016
29 November 2016. Related: Conference reports.
2nd HIV Research for Prevention Conference (HIVR4P) 2016, 17-20 October 2016, Chicago
29 November 2016. Related: Conference reports, HIV prevention and transmission.
A burgeoning PrEP pipeline: dozens of new drugs, formulations and delivery options
29 November 2016. Related: Conference reports, HIV prevention and transmission.
Second case of drug resistant HIV infection in person adherent on PrEP
29 November 2016. Related: Conference reports, HIV prevention and transmission.
TDF/FTC can be used as PrEP by breastfeeding mothers without risk to the baby
29 November 2016. Related: Conference reports, Pregnancy, HIV prevention and transmission.
Potential for EFdA as PrEP to prevent HIV transmission in women and their infants
29 November 2016. Related: Conference reports, HIV prevention and transmission.
Antibody therapy leads to sustained post-treatment SIV control in macaques
29 November 2016. Related: Conference reports, Cure-related research.
FDA approves maraviroc for children aged two and older
29 November 2016. Related: Antiretrovirals, Paediatric care.
Ibalizumab infusion reduces viral load in people with HIV multi-drug resistance
29 November 2016. Related: Antiretrovirals.
GSK discontinues development of maturation inhibitor BMS-955176
29 November 2016. Related: Antiretrovirals.
CHAI’s ARV market report shows more people than ever on ART in 2015 – and on better ART: but still some way to go
29 November 2016. Related: Treatment access.
New online database for patent expiry dates in low- and middle-income countries
29 November 2016. Related: Treatment access, On the web.
Global Fund is $2.6 billion short for 2017-2019: only $10.3 rather than 12.9 billion is available
29 November 2016. Related: Treatment access.
Dolutegravir use in a London cohort – including nine pregnant women
29 November 2016. Related: Pregnancy.
HIV positive and HIV negative pregnancies in the UK and Ireland have similar outcomes including for older women: impressive 15-year review
29 November 2016. Related: Pregnancy.
Factsheets for switching to Rezolsta (darunavir/c) or Evotaz (atazanavir/c)
29 November 2016. Related: Guidelines.
EACS Guidelines updated (October 2016)
29 November 2016. Related: Guidelines.
Swedish guidelines updated (November 2016)
29 November 2016. Related: Guidelines.
UK 2015 HIV statistics: high engagement with ART but new infections in gay men and late diagnosis overall still high
29 November 2016. Related: HIV prevention and transmission, Other news.
NHS England had no legal basis to delay PrEP: Court of Appeal upholds judgement
29 November 2016. Related: HIV prevention and transmission.
NICE evidence review supports efficacy of Truvada as PrEP in the UK
29 November 2016. Related: HIV prevention and transmission.
Conference materials online
29 November 2016. Related: On the web.
Tenofovir alafenamide (TAF) approved in US to treat hepatitis B with EU set to follow
29 November 2016. Related: Hepatitis coinfection.
November/December 2016: Volume 17 Number 11/12
29 November 2016. Related: PDFs.
September/October 2016: Volume 17 Number 9/10
1 October 2016. Related: Editorial.
18th International Workshop on Comorbidities, 12-13 September, New York, USA
1 October 2016. Related: Conference reports.
Fanconi-like lab abnormalities reported with daily PrEP: shows importance of routine kidney monitoring
1 October 2016. Related: Conference reports, Side effects, HIV prevention and transmission.
Bone loss with PrEP in MSM aged 18-24
1 October 2016. Related: Conference reports, Side effects, HIV prevention and transmission.
Neurological side effects with integrase inhibitors cause low rates of discontinuation in clinical practice
1 October 2016. Related: Conference reports, Side effects.
Atripla three days a week for two years: pilot switch study reports undetectable viral load with better bone, kidneys and sleep
1 October 2016. Related: Conference reports, Treatment strategies.
Raltegravir increases waist circumference more than boosted PIs: greater with use of later ART
1 October 2016. Related: Conference reports, Side effects.
Exercise associated with significantly reduced risk of serious health problems and higher CD4 counts in large multicentre US study
1 October 2016. Related: Conference reports, Research studies.
21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa
1 October 2016. Related: Conference reports.
Four day a week ART: sub-optimal drug levels but few virological failures
1 October 2016. Related: Conference reports, Treatment strategies.
Large disparities in costs of antiretrovirals between low- and middle-income countries
1 October 2016. Related: Conference reports, Antiretrovirals, Treatment access.
High risk of virological failure and loss to follow up postpartum in South Africa
1 October 2016. Related: Conference reports, Pregnancy.
Birth weight and preterm delivery outcomes of vertically vs non-vertically infected HIV positive pregnant women
1 October 2016. Related: Conference reports, Pregnancy.
High death rates among HIV positive women postpartum accessing ARVs
1 October 2016. Related: Conference reports, Antiretrovirals, Pregnancy.
Higher rates of eye complications in HIV positive people on ART
1 October 2016. Related: Conference reports, Antiretrovirals, Coinfections and complications.
Short reports on selected Durban posters
1 October 2016. Related: Conference reports.
Global HIV Clinical Forum: Integrase Inhibitors, 16 July 2016, Durban
1 October 2016. Related: Conference reports.
Raltegravir-based third-line ART in children and adolescents
1 October 2016. Related: Conference reports, Antiretrovirals, Paediatric care.
8th International Workshop on HIV Paediatrics, 15-16 July 2016. Durban, South Africa
1 October 2016. Related: Conference reports.
Raltegravir in HIV-exposed neonates
1 October 2016. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Virological response without routine viral load monitoring in children: results from the ARROW trial
1 October 2016. Related: Conference reports, Paediatric care.
Tenofovir-containing ART reduces bone mineral density in breast feeding women: results from IMPAACT P1084s
1 October 2016. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
First generic version of dolutegravir approved by the FDA
1 October 2016. Related: Treatment access.
Brazil to start using dolutegravir first-line in its national programme
1 October 2016. Related: Treatment access.
Global Fund to reach US $13 billion target for 2017-2019: UK pledges up to $1.3 billion
1 October 2016. Related: Treatment access.
First generic TDF/FTC approved in EU
1 October 2016. Related: Antiretrovirals.
Single-pill PI-based combination submitted to EMA
1 October 2016. Related: Antiretrovirals.
Dolutegravir superior to standard dose efavirenz in WHO analysis
1 October 2016. Related: Antiretrovirals.
US DHHS guidelines updated (July 2016)
1 October 2016. Related: Guidelines.